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Abstract
Since 2009, evidence has accumulated to suggest that Tau aggregates form first in a small number of brain
cells, from where they propagate to other regions, resulting in neurodegeneration and disease. Propagation of
Tau aggregates is often called prion-like, which refers to the capacity of an assembled protein to induce the
same abnormal conformation in a protein of the same kind, initiating a self-amplifying cascade. In addition,
prion-like encompasses the release of protein aggregates from brain cells and their uptake by neighbouring
cells. In mice, the intracerebral injection of Tau inclusions induced the ordered assembly of monomeric Tau,
followed by its spreading to distant brain regions. Short fibrils constituted the major species of seed-competent Tau.
The existence of several human Tauopathies with distinct fibril morphologies has led to the suggestion that different
molecular conformers (or strains) of aggregated Tau exist.
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Introduction
Common human neurodegenerative diseases are charac-
terized by the presence of abundant ordered assemblies
with the properties of amyloid fibrils [1, 2]. These struc-
tures are typically unbranched and 10–20 nm in diameter;
they are composed of β-strands running perpendicular to
the fibre axis and β-sheets running parallel to the long axis
of the fibrils. Each inclusion has a single protein as its
major component, with Aβ, Tau and α-Synuclein being
the most commonly involved. These proteins undergo a
transformation from a soluble to an insoluble filamentous
state, with a number of intermediates. The majority of
neurodegenerative diseases is defined by one type of inclu-
sion. Alzheimer’s disease (AD), the most prevalent, is
characterized by two types of abundant inclusions, Aβ de-
posits and Tau assemblies.
Most cases of disease are sporadic, but a small per-
centage is inherited, often in a dominant manner.
Inherited cases are caused by mutations in the genes
encoding the proteins that make up the inclusions, or
proteins that increase their production. Mutations in
MAPT, the Tau gene, give rise to an inherited form of
frontotemporal dementia and parkinsonism with abun-
dant filamentous Tau inclusions in brain [3].
From genetic data, it is known that a dysfunction of
the amyloid precursor protein (APP) initiates the disease
process in familial AD [4]. The same may be true of
sporadic AD. However, it is also clear that pathological
changes in Tau correlate better with nerve cell dysfunc-
tion than Aβ deposits [5, 6]. Moreover, a close relation-
ship between tau inclusions and nerve cell loss is well
established in hippocampus and cerebral cortex [7]. Fur-
thermore, it remains to be shown how changes in APP
can cause neurotoxicity related to Tau aggregation.
For many years, cell autonomous mechanisms were
believed to account for human neurodegenerative di-
seases, implying that the same aggregation events occur
in brain cells, independently of neighbouring cells,
resulting in degeneration. In post mortem brains, protein
inclusions are present in thousands of cells. An alterna-
tive view is that the first inclusions form in a small num-
ber of cells, from where they propagate to normal cells
through non-cell autonomous mechanisms and well-
defined pathways depending on the underlying disease,
resulting in degeneration.
Propagation of pathology is commonly called “prion-
like”, referring to the intercellular spreading of protein
aggregates. The acronym “prion” stands for “protei-
naceous infectious particle”, reflecting intercellular
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propagation and interorganismal transmission [8]. There
is no evidence to suggest that Tauopathies can transfer
between humans, hence the use of “prion-like.” Propaga-
tion of aggregates requires their release into the extracel-
lular space, uptake by connected cells and seeded
aggregation of soluble proteins. Studying the underlying
mechanisms may lead to the identification of novel
therapeutic targets.
TAU isoforms
Six Tau isoforms are expressed in adult human brain
(Fig. 1a) [9]. They range from 352 to 441 amino acids
and are produced by alternative mRNA splicing of tran-
scripts from MAPT. The six isoforms are natively un-
folded and differ by the presence or absence of inserts of
29 or 58 amino acids in the amino-terminal half, and the
inclusion or not, of the 31 amino acid repeat encoded by
exon 10 of MAPT in the carboxy-terminal half. Inclusion
of exon 10 results in the production of three Tau iso-
forms with four repeats each (4R), and its exclusion in a
further three isoforms with three repeats each (3R). Big
Tau, which carries an additional large exon in the
amino-terminal half, is expressed in the peripheral ner-
vous system [10, 11]. Together with some adjoining se-
quences, the repeats constitute the microtubule-binding
domains of Tau [12].
The dwell time of Tau on individual microtubules is
short and not significantly different between isoforms
[13, 14]. Tau promoted microtubule assembly in the pro-
cesses of differentiated PC12 cells, but it is not clear if it
also stabilised microtubules. Its short dwell time on mi-
crotubules makes it possible for Tau to interact with
Fig. 1 Human brain Tau isoforms and MAPT mutations. a MAPT and the six Tau isoforms expressed in adult human brain. MAPT consists of 16
exons (E). Alternative mRNA splicing of E2 (red), E3 (green), and E10 (yellow) gives rise to six tau isoforms (amino acids 352–441). Constitutively
spliced exons (E1, E4, E5, E7, E9, E11, E12, E13) are shown in blue. E0, which is part of the promoter, and E14 are noncoding (white). E6 and E8
(violet) are not transcribed in human brain. E4a (orange) is only expressed in the peripheral nervous system. The repeats (R1-R4) are shown,
with three isoforms having four repeats each (4R) and three isoforms having three repeats each (3R). Each repeat is 31 amino acids in length.
Exons and introns are not drawn to scale. b Mutations in MAPT in cases of frontotemporal dementia and parkinsonism linked to chromosome
17 (FTDP-17 T); 49 coding region mutations and 10 intronic mutations flanking E10 are shown
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additional molecules, such as actin and protein phos-
phatase 2A. In brain, Tau is subject to a number of post-
translational modifications, including phosphorylation,
acetylation, methylation, glycation, isomerisation, O-
GlcNAcylation, nitration, sumoylation, ubiquitination
and truncation [15].
Similar amounts of 3R and 4R Tau are expressed in
the cerebral cortex of adults [16]. In developing hu-
man brain, only the shortest Tau isoform is present.
3R, 4R and 5R Tau isoforms are found in the brains
of adult chickens [17], whereas most adult rodents
express only 4R Tau. What is conserved between spe-
cies is the expression of one hyperphosphorylated 3R
Tau isoform lacking amino-terminal inserts during
vertebrate development. Similar repeats are present in
the high-molecular weight proteins MAP2 and MAP4
[18, 19]. It has been suggested that MAP4 derives
from a non-vertebrate ancestor, whereas MAP2 and
Tau may have shared a more recent common ances-
tor [20]. The genomes of Caenorhabditis elegans and
Drosophila melanogaster each encode one protein
with Tau-like repeats [21, 22].
TAU assembly
Full-length Tau assembles into filaments through some
of its repeats and adjoining sequences, with the amino-
terminal half and most the carboxy-terminus forming
the fuzzy coat [23–27]. Tau filaments from AD brain
and those assembled from expressed protein have a
cross-β structure characteristic of amyloid fibrils [28],
with their cores consisting of approximately 90 amino
acids. The core of Tau filaments overlaps with part of
the region that binds to microtubules, implying that
pathological assembly and physiological function are
mutually exclusive.
Phosphorylation of Tau negatively regulates its ability
to interact with microtubules and filamentous Tau is
abnormally hyperphosphorylated [29]. It remains to be
seen if phosphorylation is a trigger for aggregation.
Many publications equate Tau phosphorylation with ag-
gregation. This may not be correct. It has for instance
been shown that highly phosphorylated Tau forms in a
reversible fashion during hibernation [30].
In AD, chronic traumatic encephalopathy (CTE), post-
encephalitic parkinsonism and several other Tauopathies,
all six isoforms are present in the disease filaments [1]. In
AD, filaments are either paired helical or straight, with
both types sharing a common structural subunit [31]. In
other diseases-such as progressive supranuclear palsy
(PSP), corticobasal degeneration (CBD), argyrophilic grain
disease (AGD), globular glial Tauopathy (GGT) and aging-
related Tau astrogliopathy (ARTAG)-only isoforms with
4R Tau are found in the filaments [1]. In Pick’s disease
(PiD), 3R Tau isoforms predominate in the inclusions [1].
Unlike AD, these diseases lack Aβ deposits. The mor-
phologies of Tau filaments in different diseases vary, even
when they are made of the same isoforms.
It has been suggested that patients with AD-type
neurofibrillary degeneration restricted to medial tem-
poral lobe and hippocampus, who lack Aβ deposits, suf-
fer from “primary age-related Tauopathy” (PART), a
condition that differs from AD [32]. It has also been
proposed that tangle-only dementia (TD), a relatively
rare form of dementia, represents a severe form of
PART. However, the view that PART is different from
AD has been challenged, because it is clinically and neu-
ropathologically similar to what appear to be the early
pathological stages of AD [33].
The interaction in vitro between unphosphorylated,
full-length, recombinant Tau and some negatively
charged compounds, such as sulphated glycosaminogly-
cans, results in filament assembly [34, 35]. Filaments are
decorated by antibodies directed against the amino-and
carboxy-termini of Tau, but not by an antibody directed
against the repeats. These findings, which indicate that
the repeat region is inaccessible to the antibody, are
identical to those obtained in AD and other human
Tauopathies [36]. However, the mechanisms leading to
filament formation inside human brain cells in sporadic
Tauopathies remain to be identified. Heparin is probably
not involved.
Hexapeptide sequences in R2 (amino acids 275–280,
VQIINK) and R3 (amino acids 306–311, VQIVYK) are
essential for Tau filament assembly [37, 38]. Microcrys-
tals of a peptide comprising residues 306–311 formed
steric zippers [39]. In complex with microtubules, these
hexapeptide sequences are in a hairpin conformation
[40], consistent with the view that microtubule binding
and pathological assembly of Tau are mutually exclusive.
Residues 310–313 in Tau (YKPV) differ from the equiva-
lent residues in MAP2 (TKKI). When the latter were
changed to YKPV, MAP2c also assembled into filaments
[41]. The longest human brain Tau isoform (2N4R, 441
amino acids) contains cysteines in R2 (residue 291) and
R3 (residue 322). Intra-and intermolecular disulphide
bonds may play a role in the assembly of 3R and 4R Tau
into filaments.
Genetics of MAPT
The link between Tau dysfunction and neurodegenera-
tion was established through human genetics. In June
1998, mutations in MAPT were reported in a domi-
nantly inherited form of frontotemporal dementia and
parkinsonism linked to chromosome 17q21-22 [42–44].
Fifty-nine pathogenic MAPT mutations had been identi-
fied by January 2017 (Fig. 1b). Behavioural symptoms are
the most common clinical sign. However, language distur-
bances are sometimes seen, as are signs of parkinsonism
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and motor neuron disease. The ages of onset are variable,
but can be as early as in the third decade. MAPT muta-
tions are always associated with abundant Tau inclusions
in nerve cells or in both nerve cells and glial cells [3]. By
electron microscopy, Tau filament morphologies vary [45].
Mutations in MAPT account for around 5% of cases of
FTD. They are concentrated in exons 9–12 (encoding
R1-R4) and the introns flanking exon 10, and can be di-
vided into those with a primary effect at the protein level
and those affecting the alternative splicing of Tau pre-
mRNA (Fig. 1). Mutations that act at the protein level
change or delete single amino acids, reducing the ability
of Tau to interact with microtubules. Some mutations
also promote the assembly of Tau into filaments. Muta-
tions with a primary effect at the RNA level are intronic
or exonic and increase the alternative mRNA splicing of
exon 10 of MAPT. This affects the ratio of 3R to 4R iso-
forms, resulting in the relative overproduction of 4R
Tau, and its assembly into filaments. In neurons derived
from induced pluripotent stem cells of patients with in-
tronic MAPT mutations, 4R Tau was expressed during
development, unlike what happens normally [46, 47].
Aggregated Tau can show different isoform patterns,
depending on the MAPT mutations [48]. Mutations
V337M in exon 12 and R406W in exon 13 give rise to
insoluble Tau bands of 60, 64 and 68 kDa and a weaker
band of 72 kDa. Following dephosphorylation, six bands
are present that align with recombinant Tau, like what is
seen in AD. The brains of many individuals with MAPT
mutations in exons 9–13 (K257T, L266V, ΔK280, S305N,
G272V, L315R, S320F, S320Y, P332S, Q336H, Q336R,
K369I, E372G and G389R) are characterized by abun-
dant Pick bodies made predominantly of 3R Tau. As in
sporadic PiD, insoluble Tau shows strong bands of 60
and 64 kDa. However, in most cases, variable amounts
of the 68 and 72 kDa bands are also observed. A third
pattern is characteristic of MAPT mutations that affect
the alternative mRNA splicing of exon 10 (intronic mu-
tations and exonic mutations N279K, L284L, L284R,
ΔN296, N296D, N296H, N296N, S305I, S305N and
S305S). Insoluble Tau runs as two strong bands of 64
and 68 kDa and a weaker band of 72 kDa; following de-
phosphorylation, three bands are present that align with
recombinant 4R Tau (isoforms of 383, 412 and 441
amino acids). A similar pattern of pathological Tau
bands is observed for mutations in exon 10, such as
P301L, which have their primary effects at the protein
level. Aggregation of 4R Tau has also been described for
mutations I260V in exon 9, K317N in exon 11, E342V in
exon 12 and N410H in exon 13, showing that it is pos-
sible to alter 3R and 4R Tau mRNAs through mutations
located outside exon 10.
In populations of European descent, MAPT is charac-
terised by two haplotypes resulting from a 900 kb
inversion (H1) or non-inversion (H2) polymorphism
[49]. Inheritance of H1 is a risk factor for PSP, CBD and
Parkinson’s disease (PD) [48]. This has been confirmed
in genome-wide association studies. The association with
PD is particularly surprising, since PD is not charac-
terised by the presence of Tau inclusions.
For PSP and CBD, an association has also been found
with an allele at the MOBP/SLC25A38 locus, which re-
sults in elevated levels of appoptosin, a protein that acti-
vates caspase-3, which can cleave Tau [50]. This may
result in increased aggregation of 4R Tau. The asso-
ciation of H1 with PSP had a higher odds ratio than that
between APOEε4/ε4 and AD [51]. APOEε4 is the major
risk factor allele for late-onset AD [52]. H2 is associated
with increased expression of exon 3 of MAPT in grey
matter, suggesting that inclusion of exon 3 is protective
[53]. Reduced expression of 1N4R has also been asso-
ciated with H2 [54]. Tau isoforms containing exons 2
and 10 promote aggregation, whereas exon 3-containing
isoforms are inhibitory [55].
Even though all six Tau isoforms form paired helical
and straight filaments, there are no known mutations in
MAPT that give rise to AD. Tau with an A152T substitu-
tion has been reported to be a risk factor for AD, as well
as for PSP, CBD and unusual Tauopathies ([56–58], but
see also [59]).
Propagation of TAU aggregates
Tau assembly follows a nucleation-elongation mecha-
nism. Experimentally, nucleation can be circumvented
by external seeds of preformed Tau filaments. In 2009,
prion-like mechanisms were first implicated in Tau pa-
thology (Fig. 2) [60, 61]. Since then, evidence has accu-
mulated to suggest that Tau assemblies, when applied
extracellularly, can “seed” the formation of aggregates,
followed by their spreading to other cells. Because Tau is
an intracellular protein, its propagation requires seeding,
as well as aggregate uptake and release. Even though
monomeric Tau is taken up by cells, from which it can
be released, it is probably not able to seed aggregation.
Expressed 4R Tau cannot be seeded when it lacks resi-
dues 275–280 and 306–311 [62]. Aggregation inhibitors
may thus be able to reduce Tau-induced seeding and
spreading.
Uptake of ordered Tau assemblies depends on heparan
sulphate proteoglycans at the cell surface and may occur
through macropinocytosis, at least in cultured cells [63].
The seeds probably escape from endosomal vesicles and
induce the assembly of cytoplasmic Tau. Following as-
sembly, Tau aggregates are released from cells through
ill-defined mechanisms. Intracellular Tau could transfer
between cells through tunnelling nanotubes. Alterna-
tively, it could be released into the extracellular space,
either freely or inside vesicles. Antibodies may be able to
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target extracellular Tau aggregates, provided they are
not transported in vesicles. Passive immunisation with
anti-Tau antibodies has been shown to reduce the
amounts of aggregated, hyperphosphorylated Tau in
transgenic mice [64–66]. Similarly, antisense oligonu-
cleotides reduced Tau pathology [67]. The aggregation
of Tau is known to be concentration-dependent. Tau
assemblies can enter cells, where they are detected
and neutralised via a danger response mediated by
bound anti-Tau antibodies and the cytosolic Fc recep-
tor tripartite motif protein 21 (TRIM21) [68].
Microglial cells have been reported to promote Tau
propagation through exosome-dependent mechanisms
[69]. A separate study concluded that Tau was released
from cells through an exosome-independent pathway that
required heat shock cognate 70, its co-chaperone DnaJ
and synaptosomal-associated protein 23 [70]. This work
probably described the release of aggregation-incompetent
soluble tau. By contrast, optogenetic and chemogenetic
approaches have shown that an increase in neural activity
can accelerate Tauopathy in transgenic mice [71].
Tau seeds do not need to be phosphorylated, even though
seeded Tau aggregates are hyperphosphorylated [62]. Tau
assemblies may grow by incorporating unphosphorylated
Tau which then undergoes a conformational change and
becomes hyperphosphorylated. It remains to be seen if
phosphorylation of Tau can influence seeded aggregation.
The intracerebral injection of brain extracts from
mice expressing human P301S Tau with inclusions
into mice transgenic for wild-type human Tau lacking
inclusions (line ALZ17) induced the assembly of wild-
type Tau into filaments and its spreading to distant
brain regions [60]. No inclusions formed when Tau
was depleted from the extracts prior to injection. Ag-
gregated recombinant human Tau also induced inclu-
sion formation, but with a lower efficiency than
aggregated Tau from transgenic mouse brain [72, 73].
Similar differences have been described for prions,
Aβ, α-synuclein and reactive serum amyloid A assem-
blies. Recombinant Tau aggregates were more resis-
tant to disaggregation by guanidine hydrochloride
and digestion by proteinase K than Tau aggregates
from transgenic mouse brain, consistent with the
view that more stable aggregates possess lower see-
ding activity [62].
Distinct conformations of assembled Tau accounted
for differences in seeding potency. Tau filaments formed
from recombinant P301S Tau following seeding with
aggregated Tau from transgenic mouse brain (in the
absence of heparin) showed resistance to guanidine
hydrochloride, which was similar to that of Tau seeds
from the brains of mice transgenic for human P301S
Tau. The seeding potency of Tau filaments was like that
of brain-derived aggregated Tau.
Fig. 2 Induction of filamentous Tau pathology in mice transgenic for wild-type human Tau (line ALZ17) following injection with brain extracts
from symptomatic mice transgenic for human mutant P301S tau. Staining of the hippocampal CA3 region of 18-month-old ALZ17 mice with
anti-Tau antibodies AT8 and AT100 and Gallyas-Braak silver. Non-injected (left), 15 months after injection of brain extract from non-transgenic
control mice (middle) and 15 months after injection with brain extract from 6-month-old mice transgenic for human P301S Tau (right). The
sections were counterstained with haematoxylin. Scale bar = 50 μm
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When presymptomatic P301S Tau transgenic mice
were injected intracerebrally with brain extracts from
symptomatic animals, Tau inclusions formed rapidly at
the injection sites [74]. Contralateral and caudo-rostral
propagation was evident in nuclei with strong afferent
and efferent connections to the injection sites, indicating
that the spread of pathology was dependent on connec-
tivity, not proximity.
The intraperitoneal injection of brain extracts from
symptomatic P301S Tau transgenic mice into presymp-
tomatic mice promoted the formation of cerebral Tau
inclusions [75]. Aggregated Tau can thus promote inclu-
sion formation in the central nervous system of trans-
genic mice following peripheral administration. Similar
findings have been reported for prions, assembled Aβ
and assembled α-synuclein.
We dissected the molecular characteristics of seed-
competent Tau from the brains of symptomatic P301S
Tau transgenic mice (Fig. 3) [76]. Sucrose gradient
fractions caused aggregation in transfected cells only
when large Tau aggregates (>10mers) were present.
The same fractions induced the formation and
spreading of filamentous Tau in presymptomatic
transgenic mice, whereas fractions containing mo-
nomers and small Tau aggregates were inactive. By
immunoelectron microscopy, seed-competent sucrose
gradient fractions contained aggregated Tau species
ranging from ring-like structures to small fibrils.
Strains of aggregated TAU
In 2013, we showed that the intracerebral injection of
brain homogenates from humans with pathologically
confirmed Tauopathies led to the formation of neu-
ronal and glial Tau inclusions in ALZ17 mice [77].
Inclusions formed after inoculation of brain homoge-
nates from all cases of AD, TD, PiD, AGD, PSP and
CBD. Brain homogenates from patients with AGD,
PSP and CBD produced lesions similar to those of the
human disorders. With the exception of PiD (3R), the
inclusions of the Tauopathies used were made of either
4R Tau (AGD, PSP and CBD) or a mixture of 3R and
4R Tau (AD and TD).
Injection of PSP homogenates into ALZ17 mice gave
rise to silver-positive neuronal and glial Tau aggregates;
the latter were similar to tufted astrocytes, the hallmark
lesion of PSP. The injection of CBD homogenates pro-
duced neuronal inclusions and silver-positive structures
reminiscent of astrocytic plaques. With AGD homoge-
nates, argyrophilic grains and silver-negative astrocytic
Tau inclusions were seen, like in the human disease.
With the exception of PiD, Tau inclusions propagated
over time to connected brain regions. Similar inclusions,
but fewer in number, formed after the intracerebral
injection into non-transgenic mice of brain homogenates
from human Tauopathies. Similar findings have been
reported by others following the injection of AD brain
extracts into wild-type mice [78, 79].
Fig. 3 Seeding of Tau aggregation with sucrose gradient fractions from the brains of mice transgenic for human mutant P301S Tau in a cell-based
assay. The mice were aged 4.4 weeks (no symptoms, no Tau filaments) or 24.4 weeks (symptoms, abundant Tau filaments). Sucrose gradient fractions
were used to seed aggregation of Tau in HEK cells expressing 1N4R Tau with the P301S mutation. The pellet from a 100,000 g spin of seeded cells was
analysed by Western blotting for total Tau and Tau phosphorylated at S202/T205 (anti-Tau antibodies DA9 and AT8). Filamentous Tau runs
at approximately 68 kDa (HMW, high-molecular weight); non-filamentous Tau runs at approximately 59 kDa (LMW, low-molecular weight).
The positive control consisted in seeding with sarkosyl-extracted Tau from unfractionated brains of symptomatic transgenic P301S Tau
mice and the normalised positive control was seeding with sarkosyl-extracted Tau from symptomatic mice, normalised for total Tau levels
relative to those of the sucrose gradient fractions. Seeding ability correlated with the presence of the 64 kDa band in 24.4-week-old
mice (20–50% sucrose gradient fractions). No seeding was observed upon addition of sucrose gradient fractions from the brains of
4.4-week-old mice
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These findings were complemented by studies in
HEK293 cells that had been stably transfected with part
of 4R Tau (residues 244–372) with mutations P301L and
V337M fused to YFP [80]. When exposed to Tau seeds,
mutant 4R Tau aggregated. Two Tau strains were iso-
lated, based on distinct inclusion morphologies, as well
as different biochemical and structural characteristics.
Inoculation of these assemblies into the hippocampus of
young mice transgenic for human mutant P301S tau
(line PS19) induced Tau pathologies that were stable
through serial transmission. When HEK cells expressing
mutant 4R Tau were seeded with homogenates from
these brains, inclusions formed that were identical to
those present initially. In subsequent work, another 18
Tau strains were isolated [81]. It remains to be seen
how these strains relate to the molecular conformers
of aggregated Tau that are characteristic of human
Tauopathies.
Induced Tau pathology propagated serially, when brain
homogenates from ALZ17 mice that had received bila-
teral injections of brain extracts from human P301S Tau
transgenic mice 18 months earlier, were injected into 3-
month-old ALZ17 mice [77]. In a different experiment,
homogenates were prepared from the brains of non-
transgenic mice that had been injected bilaterally with
AGD brain homogenates 18 months earlier. Twelve
months after the intracerebral injection of these homo-
genates into ALZ17 mice, many neuropil threads and
Tau aggregates were present at the injection sites.
Overexpression of full-length human wild-type 2N3R
tau or mutant P301S tau resulted in seeded aggregation
upon exposure to AD seeds [68, 78]. Similar findings
were obtained when primary neurons from wild-type
mice were treated with Tau filaments from AD brain
[79]. Seeded aggregation of mutant 4R Tau (244–372)
was also observed upon exposure to CTE, PSP, CBD and
AGD brain extracts [82]. However, these findings were
at the light microscopic level. The resulting Tau filament
morphologies are not known. Different strains of ag-
gregated Tau may well exist, but additional work is
required. In particular, it will be important to deter-
mine if Tau strains from human brain possess unique
structural features.
Conclusion
The ordered assembly of Tau represents the gain of toxic
function that causes human Tauopathies. Downstream of
assembly, Tau propagation and neurodegeneration take
place. Small Tau fibrils are the major species responsible
for propagation. The molecular Tau species responsible
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